Q32 Bio Inc. cash flow to debt ratio of -218.61% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Q32 Bio Inc.'s free cash flow has increased -50.52% from $-67.79M last year to $-33.54M, signaling increasing performance

Q32 Bio Inc.'s debt to equity ratio is 0.05, which means that the company's assets are healthy financed, signaling financial stability.

Q32 Bio Inc.'s debt has decreased relative to shareholder equity from 3.33 last year to 0.05 today, signaling strengthened financials

Q32 Bio Inc. has a net cash position, so leverage is healthy.

Q32 Bio Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Q32 Bio Inc. has insufficient data to evaluate this check.

Q32 Bio Inc.'s short-term assets of $55.05M exceed its short-term liabilities of $11.35M

Q32 Bio Inc.'s return on assets of 29.16% is higher than the 5.00% threshold, indicating efficient asset utilization

Q32 Bio Inc.'s return on equity of 76.88%, is higher than 15.00%, indicating good performance

Q32 Bio Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Q32 Bio Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

Q32 Bio Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Q32 Bio Inc. has negative free cash flow, indicating cash burn

Q32 Bio Inc.'s yearly earnings has increased -162.47% since last year from $-47.73M to $29.82M, signaling increasing performance

Q32 Bio Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC 19.43% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Q32 Bio Inc.'s 3-year revenue CAGR of 100.66% is positive, indicating growing revenue over the past 3 years

Q32 Bio Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Q32 Bio Inc. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

Q32 Bio Inc. has insufficient data to evaluate this check.

Q32 Bio Inc. has an earnings yield of 10.60%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Q32 Bio Inc. is overvalued relative to its fair value price of 12.53 based on EBITDA multiple model

Q32 Bio Inc. has an EV/EBITDA ratio of 13.84x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Q32 Bio Inc. is overvalued relative to its fair value price of -235.77 based on Earnings Fair Value model

Q32 Bio Inc. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

Q32 Bio Inc. has a price-to-book ratio of 3.01x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Q32 Bio Inc. has a price-to-sales ratio of 5.93x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue